Akoya Biosciences, Inc.: debt financing — Akoya signs $30M convertible note deal with Quanterix to fund working capital and repay debt

Akoya Biosciences, Inc.

Up to $30M in convertible promissory notes to Quanterix; drawn between May 15, 2025 and merger close or July 9, 2025.
Notes bear SOFR-based interest plus margin; interest paid monthly in cash; subordinated to existing MidCap debt.
Conversion price tied to exchange ratio under Merger Agreement and Quanterix 10-day VWAP before deal.
Conversion capped at 19.99% of Akoya common stock unless stockholder approval obtained.
Registration rights agreement requires Akoya to file resale registration statement by August 13, 2025.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Akoya Biosciences, Inc. incurred convertible notes of up to $30,000,000 with Quanterix Corporation at SOFR interest rate plus an applicable margin specified in the Convertible Note maturing the earliest to occur of (i) the 91st day following the earlier of (a) November 1, 2027 and (b) the date that Akoya’s indebtedness under the Credit and Security.

Instrument: convertible notes
Principal: up to $30,000,000
Counterparty: Quanterix Corporation
Rate: SOFR interest rate plus an applicable margin specified in the Convertible Note
Maturity: the earliest to occur of (i) the 91st day following the earlier of (a) November 1, 2027 and (b) the date that Akoya’s indebtedness under the Credit and Security
Event: incurrence

Exact text from the filing

On April 2, 2025, Akoya Biosciences, Inc. (“Akoya”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Quanterix Corporation (“Quanterix”), pursuant to which Akoya will issue and sell to Quanterix from time to time, in a private placement, one or more convertible promissory notes having an aggregate principal amount of up to $30,000,000 (the “Convertible Notes”).

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001104659-25-032006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.